First-line Atezolizumab Plus Nab-paclitaxel for Unresectable, Locally Advanced, or Metastatic Triple-negative Breast Cancer: IMpassion130 Final Overall Survival Analysis
Overview
Authors
Affiliations
Background: Guidelines recommend atezolizumab plus nab-paclitaxel (A + nP) for first-line treatment of unresectable, locally advanced, or metastatic triple-negative breast cancer expressing programmed death-ligand 1 (PD-L1) on tumor-infiltrating immune cells (IC), based on IMpassion130. We report the final overall survival (OS) and safety of that study as per the prespecified analysis plan.
Patients And Methods: Patients were randomized to nP 100 mg/m (days 1, 8, and 15 of a 28-day cycle) with atezolizumab 840 mg (A + nP) or placebo (P + nP; days 1 and 15), until progression or unacceptable toxicity. Coprimary endpoints were progression-free survival [intention-to-treat (ITT) and PD-L1 IC-positive populations] and OS (tested hierarchically in the ITT population and, if significant, in the PD-L1 IC-positive population).
Results: Each arm comprised 451 patients; 666 (73.8%) had died by the final OS analysis cut-off (median follow-up, 18.8 months; interquartile range, 8.9-34.7 months). Median OS in the ITT population was 21.0 months [95% confidence interval (CI), 19.0-23.4 months] with A + nP, and 18.7 months (95% CI, 16.9-20.8 months) with P + nP [stratified hazard ratio (HR), 0.87; 95% CI, 0.75-1.02; P = 0.077]. Exploratory analysis in the PD-L1 IC-positive population showed a median OS of 25.4 months (95% CI, 19.6-30.7 months) with A + nP (n = 185) and 17.9 months (95% CI, 13.6-20.3 months) with P + nP (n = 184; stratified HR, 0.67; 95% CI, 0.53-0.86). Safety outcomes were consistent with previous analyses and the known toxicity profiles of each agent. Immune-mediated adverse events of special interest were reported in 58.7% and 41.6% of patients treated with A + nP and P + nP, respectively.
Conclusion: Although the OS benefit in the ITT population was not statistically significant, precluding formal testing, clinically meaningful OS benefit was observed with A + nP in PD-L1 IC-positive patients, consistent with prior interim analyses. This combination remained safe and tolerable with longer follow-up.
Sun Z, Liu C, Yao Y, Gao C, Li H, Wang L Medicine (Baltimore). 2025; 104(10):e41739.
PMID: 40068043 PMC: 11903016. DOI: 10.1097/MD.0000000000041739.
Cottrell T, Lotze M, Ali A, Bifulco C, Capitini C, Chow L J Immunother Cancer. 2025; 13(3).
PMID: 40054999 PMC: 11891540. DOI: 10.1136/jitc-2024-010928.
Divide and Conquer-Targeted Therapy for Triple-Negative Breast Cancer.
Nedeljkovic M, Vuletic A, Mirjacic Martinovic K Int J Mol Sci. 2025; 26(4).
PMID: 40003864 PMC: 11855393. DOI: 10.3390/ijms26041396.
Wei Y, Ge H, Qi Y, Zeng C, Sun X, Mo H Clin Transl Med. 2025; 15(3):e70255.
PMID: 40000397 PMC: 11859116. DOI: 10.1002/ctm2.70255.
A novel HVEM-Fc recombinant protein for lung cancer immunotherapy.
Yao Y, Li B, Wang J, Chen C, Gao W, Li C J Exp Clin Cancer Res. 2025; 44(1):62.
PMID: 39979981 PMC: 11841141. DOI: 10.1186/s13046-025-03324-8.